Trial Profile
AA Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 08 Sep 2016 Status changed from active, no longer recruiting to completed.
- 14 Mar 2016 Planned End Date changed from 1 Jan 2016 to 1 May 2016 as per ClinicalTrials.gov record.
- 25 Feb 2016 Results (post hoc pooled analysis of GS-US292-0102 and GS-US292-0104 studies, n = 1733) assessing long term renal safety presented at the 23rd Conference on Retroviruses and Opportunistic Infections.